PMID: 9167761Jun 1, 1997Paper

Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma

American Journal of Clinical Oncology
N Niitsu, M Umeda

Abstract

Etoposide produces reversible inhibition of topoisomerase II, leading to cleavage of DNA, and thereby has an antitumor effect. This mechanism suggests that the longer treatment is continued, the greater the antitumor effect will be. In the present study, both therapeutic and adverse effects of long-term treatment with low-dose oral etoposide were studied in 29 patients aged > or = 65 years with non-Hodgkin's lymphoma (NHL) for whom standard chemotherapy was not effective or refractory. These patients received etoposide at a dose of 50 mg/d for as long as possible. Treatment was continued until white blood cell count decreased to < or = 2,000/microL or the platelet count decreased to < or = 5 x 10(4)/microL. According to the World Health Organization (WHO) criteria of therapeutic effects, 6 (20.7%) of the 29 patients achieved complete remission and 13 patients (44.8%) had partial remission, for a response rate of 65.5%. Adverse effects of > or = grade 3 included leukopenia in 24 patients (82.8%) and anemia in 7 (24.1%). Granulocyte colony-stimulating factor (G-CSF) was given in combination with etoposide to eight patients because of leukopenia (granulocyte count < or = 1,000/microL). In view of the excellent subjective tolerance...Continue Reading

References

Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J D HainsworthF A Greco
May 1, 1985·Annals of Internal Medicine·P Klimo, J M Connors
Mar 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Mar 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F CabanillasT Smith
Oct 1, 1971·Journal of Medicinal Chemistry·C Keller-JuslénA von Wartburg
Jan 1, 1981·Cancer·A B MillerA Winkler

❮ Previous
Next ❯

Citations

Apr 25, 2003·Critical Reviews in Oncology/hematology·Stuart M LichtmanSunitha Vemulapalli
Mar 29, 2000·Critical Reviews in Oncology/hematology·S M Lichtman
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Apr 4, 2002·Drugs & Aging·J Andrew Skirvin, Stuart M Lichtman
Jul 24, 2003·Drugs & Aging·Veena JohnStuart Lichtman
Jan 13, 2012·Veterinary and Comparative Oncology·T N LeachD W Knapp
Jan 31, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V A MorrisonS M Lichtman
Jun 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V A MorrisonS M Lichtman
Mar 23, 2010·Critical Reviews in Oncology/hematology·A GutiérrezJ Rodríguez

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.